IL17A and Cognitive impairment: Whereas MHCII has been associated with improved outcomes in AD [6], increased IL-17A levels have recently been found to help lead to the onset of cognitive deficits and synaptic alterations [51], indicating the need to understand in more detail the MR1/MAIT cell axis in AD and how it contributes to pathology overall.